Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials

This meta‐analysis compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. For dichotomous variables, the relative risk ratio (RR) and...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2016-12, Vol.5 (12), p.3454-3463
Main Authors: Xin, Yong, Guo, Wen Wen, Huang, Qian, Zhang, Pei, Zhang, Long‐Zhen, Jiang, Guan, Tian, Ye
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bias
Breast cancer
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Cancer therapies
Chemotherapy
Clinical Cancer Research
Clinical trials
Congestive heart failure
Diarrhea
Drug dosages
Epidermal growth factor
ErbB-2 protein
Female
HER2‐positive
Humans
Immunotherapy
Inhibitor drugs
Lapatinib
Medical prognosis
Meta-analysis
Monoclonal antibodies
Neutropenia
Odds Ratio
Original Research
Quality
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Randomized Controlled Trials as Topic
Receptor, ErbB-2 - metabolism
Studies
Targeted cancer therapy
Toxicity
Trastuzumab
Trastuzumab - administration & dosage
Trastuzumab - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This meta‐analysis compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. For dichotomous variables, the relative risk ratio (RR) and 95% confidence interval (CI) were used to investigate outcome measures: pathological complete response (pCR), neutropenia, diarrhea, dermatologic toxicity, and congestive heart failure (CHF). Eight randomized controlled trials of 2350 participants (837 receiving lapatinib, 913 trastuzumab, and 555 combination therapy) were selected to compare the efficiency and safety of lapatinib to trastuzumab. A significant difference was found between lapatinib and trastuzumab for pCR (RR = 0.82, 95% CI: 0.73–0.93; Z = 3.00; P = 0.003). In six studies, a significant difference was found between trastuzumab and combination therapy for pCR (RR = 1.33, 95% CI: 1.18–1.50; Z = 4.70; P 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.963